Q-omics provides the consensus-scored MIR5707 profile across patient tissues and cancer cell-line models. MIR5707 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR5707 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, MIR5707 RNA expression shows 7,256 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, COAD, and ESCA as cancer lineages where MIR5707 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5707 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5707 survival associations across molecular data types. MIR5707 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5707 RNA expression–survival associations across cancer types. High MIR5707 expression shows unfavorable associations in ACC, BLCA, MESO, UCEC, KIRP and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR5707 RNA expression.
This table summarizes MIR5707 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5707. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5707 shows lower tumor expression in COAD and higher tumor expression in BRCA and PRAD. The COAD box plot shows higher MIR5707 RNA expression in normal versus tumor tissue (log2 FC = −0.395, t-test p = .001).
This table shows molecular features associated with MIR5707 in patient tissues and cancer cell lines. In patient samples, MIR5707 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
